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Abstract
Nitric oxide (NO) is a crucial molecule in the human body. The encapsulation of exogenous NO 
donors into chitosan nanoparticles (CS NPs) has been widely used to overcome NO drawbacks in 
pharmacological applications, such as, its short half-life. The NO donor, S-nitrosoglutathione (GSNO), was 
encapsulated into CS NPs (GSNO-CS NPs) and characterized by AFM and DLS measurements. The 
nanoparticles presented a hydrodynamic size of 123.3 ± 1.5 nm and a polydispersity of 0.25 ± 0.01. The 
ability of GSNO-CS NPs, combined with UV irradiation, to deliver NO was evaluated using ex vivo human 
skin. The human skin was pre-treated with GSNO-CS NPs, in the presence and absence of UV irradiation. 
The results showed that the combined treatment significantly increased the NO and S-nitrosothiol levels in 
human skin. This effect can emulate the cardiovascular benefits related to NO without negative side effects 
of skin exposure to UV light.
Keywords: Nitric oxide, S-nitrosothiols, Nanoparticles, Human skin.
1. Introduction
As nitric oxide (NO) is involved in different biological processes [1-9], several strategies have been 
used to delivery NO in biomedical applications, and in this context, there is a great interest to increase 
endogenous NO levels [1]. The administration of exogenous NO is limited by its short half-life (seconds), 
which can restrict the biological reach of NO regarding time, concentration and site [2,3]. There are 
promising approaches to increase endogenous levels of NO, for examples, the use of delivery systems 
capable of releasing NO and/or ultraviolet (UV) irradiation [4,5], which might enrich the levels of natural 
NO storage. 
One of the natural storage of NO in the human body is the skin tissue. Human skin can store more 
stable species of NO, such as nitrite (NO2-), nitrate (NO3-), and S-nitrosothiols (RSNOs) [6–8]. These NO 
stores can be decomposed releasing free NO upon UV irradiation such as sun exposure. Once released from 
the skin, bioactive NO can reach the bloodstream causing the vasodilation of arteries, decreasing peripheral 
resistance [8], which decreases the arterial blood pressure [9], and thus promoting beneficial effects for the 
cardiovascular system [8,10].
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Another approach to increase the levels of NO in vivo is the administration of exogenous materials 
capable of carrying and delivering NO in a sustainable manner [4,5]. RSNOs are a class of NO donor 
composed of thiol-containing molecules bound to NO through an S-NO bound, for example, S-
nitrosoglutathione (GSNO) [11]. GSNO undergoes a spontaneous decomposition yielding free NO and 
oxidized glutathione (GS-SG) [12]. This reaction can be catalyzed by light exposure (UV and/or visible 
light), heat, the presence of copper ions or enzymes [11,12]. Recent progress has been achieved by using 
topical creams/ointments containing NO donors (such as GSNO), along with a reagent that can accelerate 
NO release from the RSNOs in the absence of UV light [13]. In this sense, a topical GSNO/Vaseline mixture 
using a commercial zinc oxide-containing cream was used to topical antimicrobial applications [14]. In a 
similar approach, ascorbic acid was used to trigger NO decomposition from RSNO-modified NO-releasing 
chitosan oligosaccharides, as antibacterial agents [15].
Currently available NO donors have several disadvantages, such as the release of NO below the 
therapeutic range and the instability and/or short duration of action of the NO donor [11]. One approach to 
the address this drawback is the combination of nanomaterials with NO donors, which has promising 
implications in pharmacology and biomedical fields [1]. There are several studies from our research group 
showing the successful incorporation of RSNOs into chitosan nanoparticles (CS NPs) for antimicrobial [16], 
anticancer [17,18], antiparasitic effects [19,20], and for the promoting NO release in human skin [5]. 
CS NPs and other chitosan-based materials have been studied as drug-delivery system with enhanced 
cellular uptake of the encapsulated active drugs [21], for tissue regeneration with major focus on skin 
[22,23], and for antibacterial treatment [24]. Chitosan (CS) has suitable properties for biomedical and 
pharmacological applications because of its biocompatibility, biodegradability and mucoadhesive behavior 
[22]. In addition, the encapsulation of RSNOs into CS NPs promotes a sustained NO release from the NO 
donor creating a viable material for clinical applications [25].
Since the nineties, there has been an intense and increasing research focused on the investigation of 
NO roles in the cardiovascular system [8,26–29]. More recently, it has been demonstrated that human skin is 
an important NO store (NO pool) in the forms of NO2-, NO3-, and RSNOs that can release NO from the 
human skin to the bloodstream, under the application of UV light [7,30]. GSNO is the most abundant RSNO 
found in vivo and it undergoes a spontaneous decomposition releasing NO. This reaction can be catalyzed by 
UV and/or visible irradiation [5,6,8,28,30–36] and indeed, UV irradiation can be used to increase GSNO 
decomposition and, consequently, increase the rates of NO release [5–8,30,34]. Pelegrino et al. showed that 
pre-treatment of human skin samples with GSNO-CS NPs under UV exposure increased NO levels in 
epidermis and dermis layers, as measured by confocal microscopy [5]. However, there is still the need of a 
systematic and thorough study to better comprehend the interactions between NO donors and UV light. 
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UV light has negative side effects, such as premature aging and skin cancer. Thus, in this study, we 
aimed to develop a strategy to increase NO levels in the skin, by applying NO-releasing CS NPs, without 
greater exposition to UV light, and thus avoiding harmful effects of sunlight. Moreover, in this study, we 
evaluated the formation of NO and RSNOs in human skin after different wavelength of UV light treatments 
(290 - 400 nm), combined with skin pre-treatment with CS NPs containing GSNO.
2. Materials and Methods
The effects of the application of different wavelengths of UV light on the formation of NO from 
GSNO and GSNO-CS NPs was evaluated by in vitro analysis in aqueous solutions and in ex vivo analysis in 
skin samples. The GSNO used in this study was synthesized by the nitrosation reaction of glutathione 
(GSH). The GSNO-CS NPs used were prepared by ionotropic gelation process, followed by the nitrosation 
of the free thiol group of encapsulated GSH in CS NPs. A single grating monochromator was used to 
irradiate the aqueous and skin samples with UV light at different wavelengths and energy doses. Human 
skin samples were acquired from Murrayfield private hospital. The decomposition of free or encapsulated 
GSNO was measured in the in vitro experiments by using UV-Visible spectrophotometric analysis and the 
free NO and RSNO levels from treated and untreated skin slices were measured using a nitric oxide 
electrochemical sensor. More information regarding the chemicals, the GSNO and nanoparticle preparation 
and characterization are available in the supplementary data published alongside this study.
3. Results and discussion
Firstly, to better comprehend the photochemistry of GSNO in the skin, it is needed to study the 
photochemistry of GSNO itself. Thus, the results of this study are divided into two sections: the first section 
aims to evaluate the effects of UV light irradiation, at different wavelengths, in in vitro analysis of free and 
encapsulated GSNO in aqueous solution, and the second section their effects in ex vivo skin analyses.
3.1. GSNO decomposition with NO release – in vitro analysis
To evaluate the NO release profile generated by free GSNO and GSNO-CS NPs, under UV light 
irradiation, the solutions (free GSNO or encapsulated GSNO both at 1 mM) were irradiated with 
monochromatic UV light with varying wavelengths from 260 to 320 nm. For each selected wavelength, the 
UV-Visible spectra were collected for each solution with varying energy doses from 0 to 10 J/cm². The 
amount of NO released over time was calculated based on the amount of GSNO decomposition, calculated 
by Beer-Lambert law at 336 nm, characteristic GSNO absorption band. This data showed that for a same 
wavelength, the generation of NO presents an initial linear growth and subsequent saturation with the 
increase of energy dose. As the focus of this study was to analyze the variations in the NO production as a 
function of the applied irradiation doses, the released NO concentration was normalized by diving it by its 
maximum saturation value. More details are available at the supplementary data.
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Fig. 1-(a) and (b) show the contour maps of generated NO from the decomposition of free GSNO 
(1.0 mM) , Fig. 1-(a), and GSNO-CS NPs (GSNO concentration of 1.0 mM), Fig. 1-(b). NO concentration is 
shown in the figure scale. The high levels of NO release from free GSNO and from GSNO-CS NPs were 
156.4 - 208.5 µM and 56.0 - 74.7 µM, respectively (colors red to yellow). The moderate levels of NO 
release from GSNO and GSNO-CS NPs were 78.2 - 156.4 µM and 28.0 - 56.0 µM, respectively (colors 
green to light blue). In addition, the low levels of NO release from GSNO and GSNO-CS NPs were 0.0 - 
78.2 µM and 0.0 - 56.0 µM, respectively (color blue to purple).
Fig. 1. Contour maps for photochemical NO generated from (A) free GSNO aqueous solution and (B) GSNO-CS NPs under UV irradiation 
with different wavelengths. In both cases, GSNO concentration was 1.0 mM.
Fig. 1-(a) shows the NO release profile from free and encapsulated GSNO as a function of energy 
dose, for each tested wavelength ranging from 260 to 320 nm. NO release from aqueous GSNO solution 
reached a maximum peak at 310 nm that corresponds to 208.5 µM of NO released. High levels of NO (166.8 
– 208.5 µM) were generated upon GSNO under irradiation at wavelengths between 290 - 320 nm with 
amplitude of 30 nm. Under irradiation at 280 nm, NO release was considered moderate (83.4-104.3 µM). 
Noteworthy, the maximum peak at 310 nm is the same wavelength used for most effective treatment of 
psoriasis and eczema[37]. This correlation suggests an influence of GSNO decomposition and NO release 
on psoriasis and eczema treatment. 
Fig. 1-(b) shows the NO release from GSNO-CS NPs as a function of energy dose for each tested 
wavelength ranging from 260 to 320 nm. NO release from GSNO-CS NPs reached a maximum at 300 nm 
that corresponds to 74.7 µM of NO released. Moreover, high to moderate levels of NO (67.2 – 74.7 µM) 
were obtained upon GSNO-CS NPs irradiation at 285-305 nm with an amplitude of 20 nm. The intensity of 
NO release from GSNO-CS NPs was observed to be lower for irradiation at shorter wavelengths (below 285 
nm) (7.5 – 14.9 µM) and higher for irradiation with wavelengths longer than 305 nm (7.5 – 14.9 µM). 
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The incorporation of GSNO into CS NPs decreased the total amount of NO generation and narrowed 
the spectral window in which NO was released compared to free GSNO. This effect might be related to the 
UV absorbance peak of CS NPs (see supplementary data), which can protect GSNO from decomposition 
under UV irradiation. The maximum levels of NO release from free GSNO was 208.5 µM at 310 nm, while 
for GSNO-CS NPs, the maximum NO release was 74.7 µM at 300 nm. Thus, a ca. 2.8-fold higher NO 
release was observed for free GSNO in comparison with encapsulated GSNO. This result indicates that CS 
NPs are suitable for the delivery of GSNO, since CS layer might act as a protection barrier, decreasing the 
rates of GSNO light induced decomposition, in comparison with free GSNO, under the same experimental 
conditions. Furthermore, it should be noted that the maximum wavelength for NO release from GSNO 
photodecomposition shifted from 310 to 300 nm upon GSNO incorporation into CS NPs. This effect might 
be attributed to the incorporation and interactions of GSNO with CS NPs [25]. For a clinical application, not 
only NO release parameter should be analyzed but the safety ones. It is known in literature that irradiation at 
300 nm is much more likely to cause erythema (redness) and DNA damage than 310 nm[37].  
Fig. 2 shows the NO release from GSNO and GSNO-CS NPs upon UV irradiation (260 - 320 nm) 
varying energy doses of 0 - 10 J/cm2. The dose of applied energy to skin is an important parameter to assess 
therapy safety. There are currently 225 clinical trials related to light therapy registered in clinicaltrials.gov 
domain, 72 % of these trials are related to skin diseases treatments. Among several clinical trials, UVA (340 
- 400 nm) energy dose was found to be ca. 70-130 J/cm² related to the treatment of scleroderma [38] and for 
atopic dermatitis treatment [39]. UVB (290 - 320 nm) energy dose was found to be around 0.32 - 4.0 J/cm-², 
which is related to treatment of dermatoses and keloids [39].  In addition, narrow UVB is the most effective 
treatment for psoriasis and eczema[37]. Therefore, the energy doses applied in this study can be considered 
safe for clinical applications and not harmful to skin.
It is important to highlight that the dose of energy applied in different UV ranges has different 
biological effects [37]. For examples, 1 mJ of irradiation at UVB range causes more DNA damage compared 
to the same energy dose of irradiation at UVA range [40]. Therefore, to ensure the safety treatment 
involving UV irradiation, it is important to evaluate the dose energy, as well the UV range [37,40].
The analysis of NO responses to dose (NODR) relates the efficiency of NO release in each applied 
energy dose as a function of the wavelength. Fig. 2  shows NODR for free GSNO and for GSNO-CS NPs, 
under irradiation with 260 - 320 nm. The desirable feature is obtained when a low energy dose can generate 
a high amount of NO from GSNO photodecomposition. Figure 2 shows different profiles of NO 
photogenerated from free or encapsulated GSNO upon irradiation with different wavelengths. For free 
GSNO, the curve of NODR as a function of wavelength shows two minimums points, which are centered at 
260 and at 290 nm (Fig. 2. In contrast, GSNO-CS NPs have five minimums points centered at 260, 270, 280, 
300 and 320 nm (Fig.2). These minimums points indicate that irradiation of the NO donor with this specific 
wavelength needs high energy to achieve NO photogeneration. Overall, GSNO-CS NPs showed lower 
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NODR values, in comparison with free GSNO, in all tested wavelength range. This result might be 
explained by considering the absorbance of light by CS NP layer (see the supplementary data), since 
encapsulation of GSNO into CS NPs protects the NO donor from photodegradation. 
 
Fig. 2. NO release responses to applied dose of energy (NODR) from free and encapsulated GSNO (1.0 mM) (n=3).
The NODR values reported in this study are in accordance with the literature. The values indicate a 
high efficiency of NO release in both materials tested and they are expected to have a beneficial effect in a 
future clinical application. For example, Liu et al. reported a decrease in the blood pressure after 20-30 min 
of UVA irradiation (320-400 nm at 20 J/cm²), in health volunteers (the energy generated in this application 
is related to NO generation with high efficiency (NODR ~ 1) [7]. 
Taken together, UV irradiation triggers NO release from either free or encapsulated GSNO. The NO 
generation from GSNO and from GSNO-CS NPs has similar maximum peaks at 310 and 300 nm, 
respectively. The incorporation of GSNO into CS NPs decreases the magnitude of NO release from GSNO-
CS NPs, compared to free GSNO, in almost all tested wavelengths.
3.1. GSNO decomposition with NO release – ex vivo analysis
Pelegrino et al. showed that pre-treatment of human skin samples with GSNO-CS NPs increased NO 
levels in epidermis and dermis layers, as measured by confocal microscopy [5]. We have demonstrated that 
once encapsulated in CS NPs, GSNO diffused from the polymeric matrix to the exterior solution, where the 
intact GSNO releases free NO by S–N cleavage 14. In this present work, human skin samples were pre-
treated with GSNO-CS NPs (at final GSNO concentration of 100 mM for 2.5 h), in the dark. After this 
incubation time, the skin samples were twice washed with Milli-Q water and subsequently irradiated at 280 
or at 320 nm (3.0 J/cm²). The control group consists of skin samples not pre-treated and not irradiated. After 
this process, both free NO released and the RSNO levels were measured using the NO meter attached to the 
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NO electrochemical sensor. We selected two wavelengths, at 280 and at 320 nm, (both at 3.0 J/cm²) to 
irradiate the skin samples. This selection was based on the fact that irradiation of aqueous solution of GSNO 
at 280 or at 320 nm led to NO photorelease at moderate (78.2-156.4 µM) and high levels (156.4-208.5 µM), 
respectively, as shown in Fig. 1. In addition, these two wavelengths (280 and 320 nm) showed superior 
values of NODR, compared to the values obtained for irradiation with other wavelengths (Fig. 2). In human 
skin, there are abundant levels of GSNO and other photolabile molecules capable of releasing NO upon 
irradiation (UV and visible) [5–8,30,34].
Fig. 3 shows that the irradiation of skin samples at both wavelengths (280 and 320 nm) causes an 
increase in the NO levels, compared to control group (skin in the dark condition). The irradiation of skin 
samples at 280 nm increased NO levels to an average of 297.3 ± 9.1 pA and irradiation of skin at 320 nm 
increased NO levels reaching an average of 217.5 ± 45.0 pA. Although the irradiation at 280 nm on free 
GSNO indicates a high level of NO generation and the irradiation at 320 nm on free GSNO indicates a 
moderate level of NO generation (Fig. 1), the irradiation at these two wavelengths (280 and 320 nm) showed 
non-significant differences on human skin. The observed difference between the in vitro experiments with 
free GSNO solution and ex vivo with human skin samples might be relate to the presence of other 
photolabile molecules in skin that can affect the formation of intermediary compounds and thus, the final 
NO release.
Fig. 3. NO release in human skin after irradiation with 280 and 320 nm (3 J/cm²) and control group (skin in the dark) (n=3).
Moreover, Fig. 3 shows the effects of GSNO-CS NPs pre-treatment on human skin with and without 
irradiation at 280 or 320 nm (3.0 J/cm²). The NO levels increased after GSNO-CS NPs pre-treatment in both 
tested irradiation wavelengths (280 or 320 nm), compared with non-pre-treated skin samples. The group pre-
treated with GSNO-CS NPs and irradiated at 280 nm has shown an increase of ca. 35% in the level of NO 
released, compared to the skin irradiated at the same wavelength without pre-treatment with GSNO-CS NPs. 
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In addition, skin samples pre-treated with GSNO-CS NPs and irradiated at 320 nm have shown an increase 
of ca. 100 % higher of NO levels, compared to the skin irradiated at the same wavelength without pre-
treatment with GSNO-CS NPs (Fig. 3). The GSNO-CS NPs were able to successful delivery NO to human 
skin samples, increasing the levels of NO in the skin. Thus, the combination of skin irradiation and skin 
incubation with GSNO-CS NPs further enhanced NO levels reaching almost 2-fold higher values than 
irradiation alone.
Fig. 4 shows the quantification of RSNO levels on human skin samples after the irradiation at 280 or 
at 320 nm in the presence and/or absence of skin pre-treatment with GSNO-CS NPs, compared to human 
skin samples in the dark condition with no pre-treatment. In the absence of pre-treatment, the irradiation of 
skin at 280 nm was responsible to a 3-fold decrease of RSNO levels, compared to control group (skin in the 
dark condition). The decrease in RSNOs after skin irradiation might be attributed to RSNO decomposition 
and NO release. In contrast, irradiation at 320 nm was responsible to 2-fold increase of RSNO levels, 
compared to control group (light protected skin). Interestingly, these results indicate that skin irradiation 
with different wavelengths can reduce or increase the levels of RSNOs, in a wavelength dependent fashion. 
The RSNO formation upon UV irradiation in a biological environment may involve three pathways: (i) 
oxidation of NO forming peroxynitrite (ONOO-) that undergoes radical recombination that forms nitrogen 
trioxide (N2O3) which then can nitrosate thiol-containing molecules in biological media; ii) radical 
recombination, the combination of a thiol radial (RS∙) and the NO radial, and (iii) the binding of NO to a 
transition metal followed by RSNO formation and metal reduction [41–43].
Fig. 4. Concentrations of RSN measured in human skin after irradiation at 280 nm and at 320 nm (3 J/cm²) and for the control group (skin 
in the dark). The skin samples were pre-incubated with GSNO-CS NPs at 100 mM for 2.5 h at 25 °C (n=3).
In addition, Fig. 4 shows the quantification of RSNO content in human skin samples after pre-
treatment with GSNO-CS NPs, with and without irradiation at 280 or 320 nm. The results demonstrated an 
increase in the levels of RSNO after pre-treatment with GSNO-CS NPs, under UV irradiation at 280 and 320 
nm, as expected. The skin group pre-treated with GSNO-CS NPs and irradiated at 280 nm has shown 6-fold 
higher levels of RSNOs, compared to skin group irradiated at this same wavelength without pre-treatment 
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with GSNO-CS NPs. Moreover, the skin samples pre-treated with GSNO-CS NPs and irradiated at 320 nm 
have shown 1.6-fold higher levels of RSNO in the skin, compared to the skin group irradiated at this same 
wavelength without pre-treatment with GSNO-CS NPs (Fig. 4). Thus, the pre-treatment with GSNO-CS NPs 
significantly increased the RSNO levels on skin and the combination of GSNO-CS NPs pre-treatment with 
UV irradiation (at 280 and 320 nm) further increased the RSNO levels on human skin samples.
Overall, the NO levels in human skin samples increased after irradiation at 280 and 320 nm. The skin 
pre-treatment with GSNO-CS NPs enhanced the NO and RSNO levels compared to irradiation alone. In 
contrast, the RSNO levels in human skin was increased after irradiation at 320 nm and decreased after 280 
nm exposure. To the best of our knowledge, this is the first report to describe the increase and decrease of 
RSNOs levels in human skin by varying the UV wavelength. 
It is well-known that phototherapy, in the visible or near infrared light, has been extensively 
employed to generate cytotoxic single oxygen that can be allied to the generation of NO from versatile 
nanomaterials used in different biomedical applications, especially in the combat of cancer cells [44]. For 
instance, low molecular weight RSNOs can be allied to nanomaterials and photosensitizers to generate NO 
and single oxygen upon irradiation with near infrared light [45]. Several progresses have been achieved with 
this NO-phototherapy, mainly against cancer [46]. While visible and near infrared lights have been 
extensively employed in phototherapy, UV light is considered the major preventable risk factor for skin 
cancer. 
However, recent evidences have demonstrated that sunlight exposure is linked to beneficial effects in 
the cardiovascular system, since it may lower blood pressure [47]. Human skin contains large stores of 
nitrogen oxides, and it has been demonstrated that UV light photoreduces these stores to NO, which is 
exported to the systemic circulation, lowering blood pressure [10]. Sun exposure has been linked to 
beneficial effects in the cardiovascular system. This effect might be due to an increase of RSNO and NO2- 
levels in human skin [6–8]. It should be noted that irradiation might have negative impacts on health, such 
as, the increase of skin cancer rates and aging [8,48]. Interestingly, skin treatment with GSNO-CS NPs, in 
the absence of UV irradiation, might be a new approach to increase NO and RSNO levels in human skin and 
thus emulate cardiovascular benefits [8], without negative side effects of skin exposure to UV sunlight. 
It should be noted that, in practical applications, GSNO-CS NPs allied with light irradiation might 
find important dermatological applications in the combat of bacterial infection. We have already 
demonstrated that chitosan and alginate nanoparticles containing low molecular weight RSNOs have 
important antibacterial effects against Staphylococcus aureus and Escherichia coli 13. Moreover, GSNO-
containing Pluronic hydrogel showed significant antibacterial effect against Pseudomonas aeruginosa 21. 
The photo-NO release using nanoparticles has been extensively employed in different biomedical 
applications, including antibacterial effects. For instance, a photofunctional nanofiber engineered material 
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able to release NO and single oxygen under illumination with visible light demonstrated antibacterial effects 
[49]. Recently, photoactivatable microemulsions able to photo-release NO and single oxygen were prepared. 
The material can operate either individually or in tandem resulting in red, green or both fluorescence 
emission, photogeneration of cytotoxic NO and single oxygen, and amplified photobactericidal action 
against Staphylococcus aureus [50]. In addition, a patent describes an approach to combat dermatological 
infections, such as acne, with topical NO delivery system [51]. In this sense, further studies are required to 
evaluate the potential of GSNO-CS NPs against bacteria, in dermatological applications, associated with 
light-therapy
Since 1867, organic nitrite in diverse forms has been used in clinical to the treatment of angina 
pectoris [52]. The first organic nitrate used in clinical was amyl nitrite, which was followed by nitrate 
nitroglycerin. Despite potent vasodilatory capacity, it is rapidly attenuate by the development of nitrate 
tolerance [52,53]. Treatment based on nanoparticles delivering NO, without going to nitrate pathways, have 
an intrinsically advantage compared to currently used drugs. Skin pre-treatment with GSNO-CS NPs could 
efficiently deliver NO to skin, increase cutaneous RSNO levels and replenish NO reservoirs in the skin. UV 
irradiation, at specific wavelengths, allied to the topical application of GSNO-CS NPs further increased 
RSNO levels in human skin, as reported in this work. This increase of NO and RSNO levels in human skin 
might have positive effects on the cardiovascular system, as previously discussed [6–8,10,30,54,55].
4. Conclusions
The treatment of human skin with GSNO and UV light  promoted increased NO release and may 
also increase cutaneous RSNO stores suggesting a synergetic effect of the UV irradiation and administration 
of NO donors.
The NO generation from free GSNO or GSNO-CS NPs upon UV irradiation is dependent on the 
selected UV light wavelength. The peak of NO generation upon UV irradiation from free GSNO or 
encapsulated GSNO was 310 and 300 nm, respectively. The overall amount of NO generation and 
wavelength amplitude decreased upon GSNO encapsulation into CS NPs. This may be related to the 
protection of CS layer against GSNO photodecomposition. This effect can prolong the half-life of GSNO 
into CS NPs, making them suitable for biomedical applications. 
Human skin samples pre-treated with GSNO-CS NPs have significantly increased levels of NO and 
RSNOs. This effect was further enhanced upon the combination of GSNO-CS NPs and UV irradiation at 
280 and at 320 nm. GSNO-CS NPs can deliver NO to human skin, increasing the skin levels of RSNOs, 
which replenish the the natural NO reservoir in human skin. This effect can reproduce the cardiovascular 
benefits related to NO without negative side effects of skin exposure to UV light.
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Highlights 
● Chitosan nanoparticles (NPs) containing GSNO were synthesized and characterized.
● Chitosan layer protects GSNO from UV decomposition and increases its stability.
● Chitosan nanoparticles loaded with GSNO increased NO and RSNO levels on human 
skin.
● The combination of NPs and UV radiation further enhances NO and RSNO levels in 
skin. 
● The increase of NO and RSNO levels on skin may decrease blood pressure.
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Abstract
Nitric oxide (NO) is a crucial molecule in the human body. The encapsulation of exogenous NO donors 
into chitosan nanoparticles (CS NPs) has been widely used to overcome NO drawbacks in pharmacological 
applications, such as, its short half-life. The NO donor, S-nitrosoglutathione (GSNO), was encapsulated into 
CS NPs (GSNO-CS NPs) and characterized by AFM and DLS measurements. The nanoparticles presented a 
hydrodynamic size of 123.3 ± 1.5 nm and a polydispersity of 0.25 ± 0.01. The ability of GSNO-CS NPs, 
combined with UV irradiation, to deliver NO was evaluated using ex vivo human skin. The human skin was 
pre-treated with GSNO-CS NPs, in the presence and absence of UV irradiation. The results showed that the 
combined treatment significantly increased the NO and S-nitrosothiol levels in human skin. This effect can 
emulate the cardiovascular benefits related to NO without negative side effects of skin exposure to UV light.
Keywords: Nitric oxide, S-nitrosothiols, Nanoparticles, Human skin.
1. Introduction
As nitric oxide (NO) is involved in different biological processes [1-9], several strategies have been 
used to delivery NO in biomedical applications, and in this context, there is a great interest to increase 
endogenous NO levels [1]. The administration of exogenous NO is limited by its short half-life (seconds), 
which can restrict the biological reach of NO regarding time, concentration and site [2,3]. There are promising 
approaches to increase endogenous levels of NO, for examples, the use of delivery systems capable of 
releasing NO and/or ultraviolet (UV) irradiation [4,5], which might enrich the levels of natural NO storage. 
One of the natural storage of NO in the human body is the skin tissue. Human skin can store more 
stable species of NO, such as nitrite (NO2-), nitrate (NO3-), and S-nitrosothiols (RSNOs) [6–8]. These NO 
stores can be decomposed releasing free NO upon UV irradiation such as sun exposure. Once released from 
the skin, bioactive NO can reach the bloodstream causing the vasodilation of arteries, decreasing peripheral 
resistance [8], which decreases the arterial blood pressure [9], and thus promoting beneficial effects for the 
cardiovascular system [8,10].
Another approach to increase the levels of NO in vivo is the administration of exogenous materials 
capable of carrying and delivering NO in a sustainable manner [4,5]. RSNOs are a class of NO donor 
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composed of thiol-containing molecules bound to NO through an S-NO bound, for example, S-
nitrosoglutathione (GSNO) [11]. GSNO undergoes a spontaneous decomposition yielding free NO and 
oxidized glutathione (GS-SG) [12]. This reaction can be catalyzed by light exposure (UV and/or visible light), 
heat, the presence of copper ions or enzymes [11,12]. Recent progress has been achieved by using topical 
creams/ointments containing NO donors (such as GSNO), along with a reagent that can accelerate NO release 
from the RSNOs in the absence of UV light [13]. In this sense, a topical GSNO/Vaseline mixture using a 
commercial zinc oxide-containing cream was used to topical antimicrobial applications [14]. In a similar 
approach, ascorbic acid was used to trigger NO decomposition from RSNO-modified NO-releasing chitosan 
oligosaccharides, as antibacterial agents [15].
Currently available NO donors have several disadvantages, such as the release of NO below the 
therapeutic range and the instability and/or short duration of action of the NO donor [11]. One approach to the 
address this drawback is the combination of nanomaterials with NO donors, which has promising implications 
in pharmacology and biomedical fields [1]. There are several studies from our research group showing the 
successful incorporation of RSNOs into chitosan nanoparticles (CS NPs) for antimicrobial [16], anticancer 
[17,18], antiparasitic effects [19,20], and for the promoting NO release in human skin [5]. 
CS NPs and other chitosan-based materials have been studied as drug-delivery system with enhanced 
cellular uptake of the encapsulated active drugs [21], for tissue regeneration with major focus on skin [22,23], 
and for antibacterial treatment [24]. Chitosan (CS) has suitable properties for biomedical and pharmacological 
applications because of its biocompatibility, biodegradability and mucoadhesive behavior [22]. In addition, 
the encapsulation of RSNOs into CS NPs promotes a sustained NO release from the NO donor creating a 
viable material for clinical applications [25].
Since the nineties, there has been an intense and increasing research focused on the investigation of 
NO roles in the cardiovascular system [8,26–29]. More recently, it has been demonstrated that human skin is 
an important NO store (NO pool) in the forms of NO2-, NO3-, and RSNOs that can release NO from the human 
skin to the bloodstream, under the application of UV light [7,30]. GSNO is the most abundant RSNO found 
in vivo and it undergoes a spontaneous decomposition releasing NO. This reaction can be catalyzed by UV 
and/or visible irradiation [5,6,8,28,30–36] and indeed, UV irradiation can be used to increase GSNO 
decomposition and, consequently, increase the rates of NO release [5–8,30,34]. Pelegrino et al. showed that 
pre-treatment of human skin samples with GSNO-CS NPs under UV exposure increased NO levels in 
epidermis and dermis layers, as measured by confocal microscopy [5]. However, there is still the need of a 
systematic and thorough study to better comprehend the interactions between NO donors and UV light. 
UV light has negative side effects, such as premature aging and skin cancer. Thus, in this study, we 
aimed to develop a strategy to increase NO levels in the skin, by applying NO-releasing CS NPs, without 
greater exposition to UV light, and thus avoiding harmful effects of sunlight. Moreover, in this study, we 
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evaluated the formation of NO and RSNOs in human skin after different wavelength of UV light treatments 
(290 - 400 nm), combined with skin pre-treatment with CS NPs containing GSNO.
2. Materials and Methods
The effects of the application of different wavelengths of UV light on the formation of NO from GSNO 
and GSNO-CS NPs was evaluated by in vitro analysis in aqueous solutions and in ex vivo analysis in skin 
samples. The GSNO used in this study was synthesized by the nitrosation reaction of glutathione (GSH). The 
GSNO-CS NPs used were prepared by ionotropic gelation process, followed by the nitrosation of the free thiol 
group of encapsulated GSH in CS NPs. A single grating monochromator was used to irradiate the aqueous 
and skin samples with UV light at different wavelengths and energy doses. Human skin samples were acquired 
from Murrayfield private hospital. The decomposition of free or encapsulated GSNO was measured in the in 
vitro experiments by using UV-Visible spectrophotometric analysis and the free NO and RSNO levels from 
treated and untreated skin slices were measured using a nitric oxide electrochemical sensor. More information 
regarding the chemicals, the GSNO and nanoparticle preparation and characterization are available in the 
supplementary data published alongside this study.
3. Results and discussion
Firstly, to better comprehend the photochemistry of GSNO in the skin, it is needed to study the 
photochemistry of GSNO itself. Thus, the results of this study are divided into two sections: the first section 
aims to evaluate the effects of UV light irradiation, at different wavelengths, in in vitro analysis of free and 
encapsulated GSNO in aqueous solution, and the second section their effects in ex vivo skin analyses.
3.1. GSNO decomposition with NO release – in vitro analysis
To evaluate the NO release profile generated by free GSNO and GSNO-CS NPs, under UV light 
irradiation, the solutions (free GSNO or encapsulated GSNO both at 1 mM) were irradiated with 
monochromatic UV light with varying wavelengths from 260 to 320 nm. For each selected wavelength, the 
UV-Visible spectra were collected for each solution with varying energy doses from 0 to 10 J/cm². The amount 
of NO released over time was calculated based on the amount of GSNO decomposition, calculated by Beer-
Lambert law at 336 nm, characteristic GSNO absorption band. This data showed that for a same wavelength, 
the generation of NO presents an initial linear growth and subsequent saturation with the increase of energy 
dose. As the focus of this study was to analyze the variations in the NO production as a function of the applied 
irradiation doses, the released NO concentration was normalized by diving it by its maximum saturation value. 
More details are available at the supplementary data.
Fig. 1-(a) and (b) show the contour maps of generated NO from the decomposition of free GSNO (1.0 
mM) , Fig. 1-(a), and GSNO-CS NPs (GSNO concentration of 1.0 mM), Fig. 1-(b). NO concentration is shown 
in the figure scale. The high levels of NO release from free GSNO and from GSNO-CS NPs were 156.4 - 
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208.5 µM and 56.0 - 74.7 µM, respectively (colors red to yellow). The moderate levels of NO release from 
GSNO and GSNO-CS NPs were 78.2 - 156.4 µM and 28.0 - 56.0 µM, respectively (colors green to light blue). 
In addition, the low levels of NO release from GSNO and GSNO-CS NPs were 0.0 - 78.2 µM and 0.0 - 56.0 
µM, respectively (color blue to purple).
Fig. 1. Contour maps for photochemical NO generated from (A) free GSNO aqueous solution and (B) GSNO-CS NPs under UV irradiation 
with different wavelengths. In both cases, GSNO concentration was 1.0 mM.
Fig. 1-(a) shows the NO release profile from free and encapsulated GSNO as a function of energy 
dose, for each tested wavelength ranging from 260 to 320 nm. NO release from aqueous GSNO solution 
reached a maximum peak at 310 nm that corresponds to 208.5 µM of NO released. High levels of NO (166.8 
– 208.5 µM) were generated upon GSNO under irradiation at wavelengths between 290 - 320 nm with 
amplitude of 30 nm. Under irradiation at 280 nm, NO release was considered moderate (83.4-104.3 µM). 
Noteworthy, the maximum peak at 310 nm is the same wavelength used for most effective treatment of 
psoriasis and eczema[37]. This correlation suggests an influence of GSNO decomposition and NO release on 
psoriasis and eczema treatment. 
Fig. 1-(b) shows the NO release from GSNO-CS NPs as a function of energy dose for each tested 
wavelength ranging from 260 to 320 nm. NO release from GSNO-CS NPs reached a maximum at 300 nm that 
corresponds to 74.7 µM of NO released. Moreover, high to moderate levels of NO (67.2 – 74.7 µM) were 
obtained upon GSNO-CS NPs irradiation at 285-305 nm with an amplitude of 20 nm. The intensity of NO 
release from GSNO-CS NPs was observed to be lower for irradiation at shorter wavelengths (below 285 nm) 
(7.5 – 14.9 µM) and higher for irradiation with wavelengths longer than 305 nm (7.5 – 14.9 µM). 
The incorporation of GSNO into CS NPs decreased the total amount of NO generation and narrowed 
the spectral window in which NO was released compared to free GSNO. This effect might be related to the 
UV absorbance peak of CS NPs (see supplementary data), which can protect GSNO from decomposition under 
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UV irradiation. The maximum levels of NO release from free GSNO was 208.5 µM at 310 nm, while for 
GSNO-CS NPs, the maximum NO release was 74.7 µM at 300 nm. Thus, a ca. 2.8-fold higher NO release 
was observed for free GSNO in comparison with encapsulated GSNO. This result indicates that CS NPs are 
suitable for the delivery of GSNO, since CS layer might act as a protection barrier, decreasing the rates of 
GSNO light induced decomposition, in comparison with free GSNO, under the same experimental conditions. 
Furthermore, it should be noted that the maximum wavelength for NO release from GSNO 
photodecomposition shifted from 310 to 300 nm upon GSNO incorporation into CS NPs. This effect might 
be attributed to the incorporation and interactions of GSNO with CS NPs [25]. For a clinical application, not 
only NO release parameter should be analyzed but the safety ones. It is known in literature that irradiation at 
300 nm is much more likely to cause erythema (redness) and DNA damage than 310 nm[37].  
Fig. 2 shows the NO release from GSNO and GSNO-CS NPs upon UV irradiation (260 - 320 nm) 
varying energy doses of 0 - 10 J/cm2. The dose of applied energy to skin is an important parameter to assess 
therapy safety. There are currently 225 clinical trials related to light therapy registered in clinicaltrials.gov 
domain, 72 % of these trials are related to skin diseases treatments. Among several clinical trials, UVA (340 
- 400 nm) energy dose was found to be ca. 70-130 J/cm² related to the treatment of scleroderma [38] and for 
atopic dermatitis treatment [39]. UVB (290 - 320 nm) energy dose was found to be around 0.32 - 4.0 J/cm-², 
which is related to treatment of dermatoses and keloids [39].  In addition, narrow UVB is the most effective 
treatment for psoriasis and eczema[37]. Therefore, the energy doses applied in this study can be considered 
safe for clinical applications and not harmful to skin.
It is important to highlight that the dose of energy applied in different UV ranges has different 
biological effects [37]. For examples, 1 mJ of irradiation at UVB range causes more DNA damage compared 
to the same energy dose of irradiation at UVA range [40]. Therefore, to ensure the safety treatment involving 
UV irradiation, it is important to evaluate the dose energy, as well the UV range [37,40].
The analysis of NO responses to dose (NODR) relates the efficiency of NO release in each applied 
energy dose as a function of the wavelength. Fig. 2  shows NODR for free GSNO and for GSNO-CS NPs, 
under irradiation with 260 - 320 nm. The desirable feature is obtained when a low energy dose can generate a 
high amount of NO from GSNO photodecomposition. Figure 2 shows different profiles of NO photogenerated 
from free or encapsulated GSNO upon irradiation with different wavelengths. For free GSNO, the curve of 
NODR as a function of wavelength shows two minimums points, which are centered at 260 and at 290 nm 
(Fig. 2. In contrast, GSNO-CS NPs have five minimums points centered at 260, 270, 280, 300 and 320 nm 
(Fig.2). These minimums points indicate that irradiation of the NO donor with this specific wavelength needs 
high energy to achieve NO photogeneration. Overall, GSNO-CS NPs showed lower NODR values, in 
comparison with free GSNO, in all tested wavelength range. This result might be explained by considering 
the absorbance of light by CS NP layer (see the supplementary data), since encapsulation of GSNO into CS 
NPs protects the NO donor from photodegradation. 
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Fig. 2. NO release responses to applied dose of energy (NODR) from free and encapsulated GSNO (1.0 mM) (n=3).
The NODR values reported in this study are in accordance with the literature. The values indicate a 
high efficiency of NO release in both materials tested and they are expected to have a beneficial effect in a 
future clinical application. For example, Liu et al. reported a decrease in the blood pressure after 20-30 min 
of UVA irradiation (320-400 nm at 20 J/cm²), in health volunteers (the energy generated in this application is 
related to NO generation with high efficiency (NODR ~ 1) [7]. 
Taken together, UV irradiation triggers NO release from either free or encapsulated GSNO. The NO 
generation from GSNO and from GSNO-CS NPs has similar maximum peaks at 310 and 300 nm, respectively. 
The incorporation of GSNO into CS NPs decreases the magnitude of NO release from GSNO-CS NPs, 
compared to free GSNO, in almost all tested wavelengths.
3.1. GSNO decomposition with NO release – ex vivo analysis
Pelegrino et al. showed that pre-treatment of human skin samples with GSNO-CS NPs increased NO 
levels in epidermis and dermis layers, as measured by confocal microscopy [5]. We have demonstrated that 
once encapsulated in CS NPs, GSNO diffused from the polymeric matrix to the exterior solution, where the 
intact GSNO releases free NO by S–N cleavage 14. In this present work, human skin samples were pre-
treated with GSNO-CS NPs (at final GSNO concentration of 100 mM for 2.5 h), in the dark. After this 
incubation time, the skin samples were twice washed with Milli-Q water and subsequently irradiated at 280 
or at 320 nm (3.0 J/cm²). The control group consists of skin samples not pre-treated and not irradiated. After 
this process, both free NO released and the RSNO levels were measured using the NO meter attached to the 
NO electrochemical sensor. We selected two wavelengths, at 280 and at 320 nm, (both at 3.0 J/cm²) to irradiate 
the skin samples. This selection was based on the fact that irradiation of aqueous solution of GSNO at 280 or 
at 320 nm led to NO photorelease at moderate (78.2-156.4 µM) and high levels (156.4-208.5 µM), 
respectively, as shown in Fig. 1. In addition, these two wavelengths (280 and 320 nm) showed superior values 
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of NODR, compared to the values obtained for irradiation with other wavelengths (Fig. 2). In human skin, 
there are abundant levels of GSNO and other photolabile molecules capable of releasing NO upon irradiation 
(UV and visible) [5–8,30,34].
Fig. 3 shows that the irradiation of skin samples at both wavelengths (280 and 320 nm) causes an 
increase in the NO levels, compared to control group (skin in the dark condition). The irradiation of skin 
samples at 280 nm increased NO levels to an average of 297.3 ± 9.1 pA and irradiation of skin at 320 nm 
increased NO levels reaching an average of 217.5 ± 45.0 pA. Although the irradiation at 280 nm on free GSNO 
indicates a high level of NO generation and the irradiation at 320 nm on free GSNO indicates a moderate level 
of NO generation (Fig. 1), the irradiation at these two wavelengths (280 and 320 nm) showed non-significant 
differences on human skin. The observed difference between the in vitro experiments with free GSNO solution 
and ex vivo with human skin samples might be relate to the presence of other photolabile molecules in skin 
that can affect the formation of intermediary compounds and thus, the final NO release.
Fig. 3. NO release in human skin after irradiation with 280 and 320 nm (3 J/cm²) and control group (skin in the dark) (n=3).
Moreover, Fig. 3 shows the effects of GSNO-CS NPs pre-treatment on human skin with and without 
irradiation at 280 or 320 nm (3.0 J/cm²). The NO levels increased after GSNO-CS NPs pre-treatment in both 
tested irradiation wavelengths (280 or 320 nm), compared with non-pre-treated skin samples. The group pre-
treated with GSNO-CS NPs and irradiated at 280 nm has shown an increase of ca. 35% in the level of NO 
released, compared to the skin irradiated at the same wavelength without pre-treatment with GSNO-CS NPs. 
In addition, skin samples pre-treated with GSNO-CS NPs and irradiated at 320 nm have shown an increase of 
ca. 100 % higher of NO levels, compared to the skin irradiated at the same wavelength without pre-treatment 
with GSNO-CS NPs (Fig. 3). The GSNO-CS NPs were able to successful delivery NO to human skin samples, 
increasing the levels of NO in the skin. Thus, the combination of skin irradiation and skin incubation with 
GSNO-CS NPs further enhanced NO levels reaching almost 2-fold higher values than irradiation alone.
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Fig. 4 shows the quantification of RSNO levels on human skin samples after the irradiation at 280 or 
at 320 nm in the presence and/or absence of skin pre-treatment with GSNO-CS NPs, compared to human skin 
samples in the dark condition with no pre-treatment. In the absence of pre-treatment, the irradiation of skin at 
280 nm was responsible to a 3-fold decrease of RSNO levels, compared to control group (skin in the dark 
condition). The decrease in RSNOs after skin irradiation might be attributed to RSNO decomposition and NO 
release. In contrast, irradiation at 320 nm was responsible to 2-fold increase of RSNO levels, compared to 
control group (light protected skin). Interestingly, these results indicate that skin irradiation with different 
wavelengths can reduce or increase the levels of RSNOs, in a wavelength dependent fashion. The RSNO 
formation upon UV irradiation in a biological environment may involve three pathways: (i) oxidation of NO 
forming peroxynitrite (ONOO-) that undergoes radical recombination that forms nitrogen trioxide (N2O3) 
which then can nitrosate thiol-containing molecules in biological media; ii) radical recombination, the 
combination of a thiol radial (RS∙) and the NO radial, and (iii) the binding of NO to a transition metal followed 
by RSNO formation and metal reduction [41–43].
Fig. 4. Concentrations of RSN measured in human skin after irradiation at 280 nm and at 320 nm (3 J/cm²) and for the control group (skin 
in the dark). The skin samples were pre-incubated with GSNO-CS NPs at 100 mM for 2.5 h at 25 °C (n=3).
In addition, Fig. 4 shows the quantification of RSNO content in human skin samples after pre-treatment 
with GSNO-CS NPs, with and without irradiation at 280 or 320 nm. The results demonstrated an increase in 
the levels of RSNO after pre-treatment with GSNO-CS NPs, under UV irradiation at 280 and 320 nm, as 
expected. The skin group pre-treated with GSNO-CS NPs and irradiated at 280 nm has shown 6-fold higher 
levels of RSNOs, compared to skin group irradiated at this same wavelength without pre-treatment with 
GSNO-CS NPs. Moreover, the skin samples pre-treated with GSNO-CS NPs and irradiated at 320 nm have 
shown 1.6-fold higher levels of RSNO in the skin, compared to the skin group irradiated at this same 
wavelength without pre-treatment with GSNO-CS NPs (Fig. 4). Thus, the pre-treatment with GSNO-CS NPs 
significantly increased the RSNO levels on skin and the combination of GSNO-CS NPs pre-treatment with 
UV irradiation (at 280 and 320 nm) further increased the RSNO levels on human skin samples.
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Overall, the NO levels in human skin samples increased after irradiation at 280 and 320 nm. The skin 
pre-treatment with GSNO-CS NPs enhanced the NO and RSNO levels compared to irradiation alone. In 
contrast, the RSNO levels in human skin was increased after irradiation at 320 nm and decreased after 280 nm 
exposure. To the best of our knowledge, this is the first report to describe the increase and decrease of RSNOs 
levels in human skin by varying the UV wavelength. 
It is well-known that phototherapy, in the visible or near infrared light, has been extensively employed 
to generate cytotoxic single oxygen that can be allied to the generation of NO from versatile nanomaterials 
used in different biomedical applications, especially in the combat of cancer cells [44]. For instance, low 
molecular weight RSNOs can be allied to nanomaterials and photosensitizers to generate NO and single 
oxygen upon irradiation with near infrared light [45]. Several progresses have been achieved with this NO-
phototherapy, mainly against cancer [46]. While visible and near infrared lights have been extensively 
employed in phototherapy, UV light is considered the major preventable risk factor for skin cancer. 
However, recent evidences have demonstrated that sunlight exposure is linked to beneficial effects in 
the cardiovascular system, since it may lower blood pressure [47]. Human skin contains large stores of 
nitrogen oxides, and it has been demonstrated that UV light photoreduces these stores to NO, which is exported 
to the systemic circulation, lowering blood pressure [10]. Sun exposure has been linked to beneficial effects 
in the cardiovascular system. This effect might be due to an increase of RSNO and NO2- levels in human skin 
[6–8]. It should be noted that irradiation might have negative impacts on health, such as, the increase of skin 
cancer rates and aging [8,48]. Interestingly, skin treatment with GSNO-CS NPs, in the absence of UV 
irradiation, might be a new approach to increase NO and RSNO levels in human skin and thus emulate 
cardiovascular benefits [8], without negative side effects of skin exposure to UV sunlight. 
It should be noted that, in practical applications, GSNO-CS NPs allied with light irradiation might find 
important dermatological applications in the combat of bacterial infection. We have already demonstrated that 
chitosan and alginate nanoparticles containing low molecular weight RSNOs have important antibacterial 
effects against Staphylococcus aureus and Escherichia coli 13. Moreover, GSNO-containing Pluronic 
hydrogel showed significant antibacterial effect against Pseudomonas aeruginosa 21. The photo-NO release 
using nanoparticles has been extensively employed in different biomedical applications, including 
antibacterial effects. For instance, a photofunctional nanofiber engineered material able to release NO and 
single oxygen under illumination with visible light demonstrated antibacterial effects [49]. Recently, 
photoactivatable microemulsions able to photo-release NO and single oxygen were prepared. The material 
can operate either individually or in tandem resulting in red, green or both fluorescence emission, 
photogeneration of cytotoxic NO and single oxygen, and amplified photobactericidal action against 
Staphylococcus aureus [50]. In addition, a patent describes an approach to combat dermatological infections, 
such as acne, with topical NO delivery system [51]. In this sense, further studies are required to evaluate the 
potential of GSNO-CS NPs against bacteria, in dermatological applications, associated with light-therapy
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Since 1867, organic nitrite in diverse forms has been used in clinical to the treatment of angina pectoris 
[52]. The first organic nitrate used in clinical was amyl nitrite, which was followed by nitrate nitroglycerin. 
Despite potent vasodilatory capacity, it is rapidly attenuate by the development of nitrate tolerance [52,53]. 
Treatment based on nanoparticles delivering NO, without going to nitrate pathways, have an intrinsically 
advantage compared to currently used drugs. Skin pre-treatment with GSNO-CS NPs could efficiently deliver 
NO to skin, increase cutaneous RSNO levels and replenish NO reservoirs in the skin. UV irradiation, at 
specific wavelengths, allied to the topical application of GSNO-CS NPs further increased RSNO levels in 
human skin, as reported in this work. This increase of NO and RSNO levels in human skin might have positive 
effects on the cardiovascular system, as previously discussed [6–8,10,30,54,55].
4. Conclusions
The treatment of human skin with GSNO and UV light  promoted increased NO release and may also 
increase cutaneous RSNO stores suggesting a synergetic effect of the UV irradiation and administration of 
NO donors.
The NO generation from free GSNO or GSNO-CS NPs upon UV irradiation is dependent on the 
selected UV light wavelength. The peak of NO generation upon UV irradiation from free GSNO or 
encapsulated GSNO was 310 and 300 nm, respectively. The overall amount of NO generation and wavelength 
amplitude decreased upon GSNO encapsulation into CS NPs. This may be related to the protection of CS layer 
against GSNO photodecomposition. This effect can prolong the half-life of GSNO into CS NPs, making them 
suitable for biomedical applications. 
Human skin samples pre-treated with GSNO-CS NPs have significantly increased levels of NO and 
RSNOs. This effect was further enhanced upon the combination of GSNO-CS NPs and UV irradiation at 280 
and at 320 nm. GSNO-CS NPs can deliver NO to human skin, increasing the skin levels of RSNOs, which 
replenish the the natural NO reservoir in human skin. This effect can reproduce the cardiovascular benefits 
related to NO without negative side effects of skin exposure to UV light.
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1. Materials and Methods
1.1. Chemicals
The pure chemicals used in this work where: Glutathione (GSH), sodium nitrite (NaNO2), chitosan (CS, 
low molecular weight, 75 % of desacetylation), sodium tripolyphosphate (TPP), 5,5′-dithiobis (2-nitrobenzoic 
acid) (DTNB), ethylenediaminetetraacetic acid (EDTA), phosphate buffer (PBS), cupper chloride II (CuCl2), 
and acetic acid. These chemicals were purchased from Sigma-Aldrich (St. Loius, MO, USA) ad used without 
Supplementary Data Page 2 of 10
further purification. All experiments were carried out using high-purity water from a Millipore Milli-Q Gradient 
filtration system with resistivity not less than 18.2 MΩ·cm at 25.0 ºC. 
1.2. Synthesis of GSNO
GSNO was synthesized by the nitrosation reaction of GSH. An aqueous solution of GSH (100 mmol·L-1, 
pH 4.5) was mixed with an aqueous solution of NaNO2 (100 mmol·L-1, pH 4.5), at room temperature, for 5 min 
in the dark.  The formation of GSNO was confirmed by recording the characteristic absorbance peak of GSNO 
at 336 nm (ɛ = 980.0 mol-1·L·cm-1), by using a plate reader (BioTek, Synergy HT, Vermont, USA) [1–3].
1.3.  Synthesis of GSH-containing chitosan nanoparticles (GSH-CS NPs)
GSH-containing chitosan nanoparticles (GSH-CS NPs) were prepared by ionotropic gelation process 
[2,3]. In brief, aqueous solutions of CS (2.6 mg·mL−1) and GSH (133.3 mmol·L-1) were homogenized in 1 % 
acetic acid for 90 min, under magnetic stirring. An aqueous TPP solution (0.6 mg·mL−1) was added dropwise to 
CS/GSH solution following the volumetric proportion of 3CS:1TPP. The final mixture was further stirred for 45 
min at room temperature to leading to the formation of CS NPs (1000 μg of CS·mL−1) containing GSH (100 
mmol·L-1). The GSH-CS NPs can be stored for at least 4 months. 
1.4.  Characterization of GSH-CS NPs
The synthesized GSH-CS NPs were characterized as described below.
1.4.1. Dynamic light scattering measurements (DLS)
The average hydrodynamic diameter (% by intensity), polydispersity index (PDI), and zeta potential of 
GSH-CS NPs were evaluated by DLS using a Nano ZS Zetasizer (Malvern Instruments Co, UK). The 
measurements were performed in three independent experiments at 25 °C using a fixed angle of 173° in 
disposable folded capillary zeta cells with a 10 mm path length in aqueous suspension.
1.4.2. GSH encapsulation efficiency into CS NPs
The encapsulation efficiency of GSH into CS NPs was measured by the quantification of free thiol 
groups using the Ellman’s reagent [2,3]. To separate the free GSH molecules from encapsulated GSH, a volume 
of 500 μL of aqueous suspension of GSH-CS NPs was filtered in a Microcon centrifugal filter device (MWCO 
10,000, Millipore). The eluted volume, containing non encapsulated GSH, was added to DTNB solution (0.7 
mmol·L-1) and EDTA (10.3 mmol·L-1) at pH 7.4. After 5 min of incubation in the dark, the absorbance at 412 
nm (ε = 14.15 mmol-1·L·cm-1) was measured in the UV-vis spectrophotometer Agilent 8454 (Palo Alto, CA, 
USA). The measurements were performed in duplicates. 
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1.4.3. Atomic force microscopy (AFM)  
In order to investigate the shape and morphology of GSH-CS NPs, topography and phase contrast 
images were simultaneously obtained by atomic force microscope (AFM, AFM/SPM Series 5500, Agilent) in 
tapping mode. The free software WSxM 5.0 Develop 8.2 was used to analyse the obtained images and plot the 
particle size histogram [4].
1.5. Nitrosation of GSH-CS NPs leading to the formation of GSNO-CS NPs 
Free thiol group of GSH encapsulated in CS NPs was nitrosated, similar as described in section 
number1.2, leading to the formation of GSNO-containing CS NPs (GSNO-CS NPs) [2,3]. To this end, aqueous 
suspension of GSH-CS NPs (GSH concentration of 100 mmol·L-1, pH 4.5) was mixed with an aqueous solution 
of NaNO2 (100 mmol·L-1, pH 4.5), at 5 – 8 ºC for 30 min in dark. The formation of GSNO into CS NPs was 
confirmed by detecting the characteristic absorbance peak of GSNO at 336 nm (ɛ = 980.0 mol-1·L·cm-1) using a 
plate reader (BioTek, Synergy HT, Vermont, USA) [1–3]. The GSNO-CS NPs should be immediately used 
after GSH nitrosation.  
1.6.  Monochromator
A single grating monochromator (model 77200, ThermoOriel, Newport, UK) with a 1000 W deuterium 
lamp was used to irradiate aqueous solutions and skin samples. The output light was attached to a liquid guide 
(5 mm diameter) to direct irradiate the samples. The wavelength calibration was conducted using a 
spectroradiometer (3AP-CAL, OphirOptronics Ltd, Jerusalem, Israel).
1.7. GSNO decomposition with NO release
The decomposition of free or encapsulated GSNO was measured by using UV-Visible 
spectrophotometric analysis. A volume of 2 mL of aqueous solution of free GSNO or aqueous suspension of 
GSNO-CS NPs (in both cases the initial GSNO concentration was 1.0 mmol·L-1) was transferred to a 12-well-
plate. The plate was positioned under the light guide connected to monochromator, described in section number 
1.6. The samples were irradiated using the liquid light guide with narrow wavelengths centered at 260, 270, 
280, 290, 300, 310, 320, 330, 340, 360, 380 and 400 nm (precision of 0.1 nm). The samples were irradiated with 
different energies of 0-10 J·cm-². The absorbance of GSNO was analyzed using the plate reader (BioTek, 
Synergy HT, Vermont, USA) by measuring the absorption intensity of GSNO at 336 nm. The decrease this 
absorption band intensity is associated with S-N bond cleavage of GSNO and free NO release [2,3]. The 
concentration of NO release over time was calculated from the amount of GSNO decomposed, through 
Equation 1and Equation 2.
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[NO]t = [GSNO]0 - [GSNO]t Equation 1
[NO]t = (A0b)/εGSNO - (Atb)/εGSNO Equation 2
Where [NO]t is NO concentration at time t, [GSNO]0 and [GSNO]t are the concentrations of GSNO at the 
beginning of reaction and at time t, respectively; A0 and At are the GSNO absorbance intensities at 336 nm at 
time zero and at time t, respectively; εGSNO is the molar absorption coefficient of GSNO at 336 nm; and b is the 
optical path of cuvette, which was normalized to 1.0 cm using the plate reader software. 
The mathematical analysis for GSNO decomposition with NO release allowed to create contour maps 
showing the intensity of NO release, as a function of the selected wavelength. The NO release was determined 
by [NO]t acquired as a function of applied energy dose (ED), at a given wavelength. This mathematical 
procedure is described with more details in Supplementary Information section and the adjusted equations 
presented a determination coefficient (R2) of no less than 0.96.
The free NO release analyses were collected using spectroscopy. This analysis reported the 
concentration of free NO in mmol·L-1. For groups of (i) free GSNO (1.0 mmol·L-1, pH 4.5), and (ii) GSNO-CS 
NPs (1.0 mmol·L-1, pH 4.5), the concentration of free NO was acquired as a function of the applied energy dose 
(ED) at a given wavelength. This data showed that for a same wavelength the liberation of NO presents an 
initial linear growth and subsequent saturation at a given signal intensity ([NO]max), as shown in Fig. 1-a. The 
equation in Fig. 1-b represents the Michaelis-Menten model and [NO]c stands for the calculated signal and EDm 
for the energy dose in which [NO]= [NO]max /2. 
Fig. 1. (a) Collected and fitted data at 320nm and (b) schematic representations of the equation fitted.
The adjusted equations presented the determination coefficient (R2) of no less than 0.96 presenting good 
fit to the data. As the focus of this study is to analyze the variation of NO production with light irradiation and 
not to quantify the amount of NO, the [NO] was normalized by dividing it by [NO]max, and henceforth reported 
as [NO]n for each wavelength and calculated using for the energy dose interval from 0 to 10 J·cm-2 for every 
experimental sample group. This analysis allowed to create a contour maps showing the intensity of NO release 
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as a function of the wavelength of ultraviolet light irradiated for every NO forming chemical species analyzed. 
In addition, to evaluate the dose response of the irradiation in the NO release of the chemical species evaluated 
it was considered that until EDm the curve of [NO]n versus ED presented linear behavior. By this consideration 
the angular coefficient is given by ([NO]n/2)/EDm and the angle between this line and the ED axis is given by 
the inverse tangent arc of this coefficient. By these considerations the NO response to dose (NODR) was 
calculated dividing the obtained angle by 90º so that if NODR approaches zero the response to the irradiation 
dose is null and if it approaches to one it is the maximum as possible for each chemical at a given wavelength, 
see Fig. 2.
Fig. 2. Schematic representation of the calculation of (a) [NO]n and (b) NODR. Both are calculates at a constant wavelength 
1.8.  Human skin samples
Human skin samples were acquired from Murrayfield private hospital from abdominoplasty surgery 
(Edinburgh, Scotland, UK). After surgery, the skin slices were cleaned and transferred to Queen Medical 
Research Institute (QMRI) facility. The skin fat layer was removed using a scalpel and scissors. The skin was 
cut using dermatological punch with 4 mm of diameter and the skin slices were stored at - 20 ºC.
1.9.  Free NO release from human skin slices pre-treated with GSNO-CS NPs
The amount of free NO release from untreated and treated human skin slices (4 mm) was measured. The 
pre-treatment consists in the incubation of skin slices with GSNO-CS NPs (GSNO concentration of 100.0 
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mmol·L-1) for 2.5 h at 25 ºC in dark. After the incubation time, the skin samples were washed twice with Milli-
Q water. Free NO release from treated and untreated skin slice was measured using the nitric oxide meter (ISO-
NO, NOMK2, World Precision Instruments, WPI, FL, USA) with an electrochemical sensor (ISONOP-4 mm). 
To this end, 7 mL of Milli-Q water was transferred to a quartz cuvette (20 mm of optical path) containing 
treated or untreated skin slice. The electrochemical sensor was immersed into aqueous solutions (ca. 1 cm 
below top of quartz cuvette) and the signal of free NO production was electrochemically monitored, in dark and 
under irradiation. For the irradiation, the treated or untreated skin slices were irradiated using a liquid guide 
with narrow wavelengths centered at 280 and 320 nm (precision of 0.1 nm) at 3.0 J·cm-². The wavelengths were 
selected by using the monochromator, as described in the section 1.6.
1.10. Quantification of RSNO levels in human skin slices
The quantification of total RSNO contents in untreated and GSNO-CS NPs pre-treated human skin slices 
(4 mm) were determined. The pre-treatment consists in the incubation of human skin slices with GSNO-CS NPs 
(GSNO concentration of 100.0 mmol·L-1) for 2.5 h at 25 ºC in dark. After the incubation time, the skin samples 
were washed twice with Milli-Q water.  The skin samples were sub-divided in the following groups: (i) samples 
irradiated at 280 nm, (ii) samples irradiated at 320 nm, (iii) non-irradiated skin samples. The irradiation was 
performed by positioning the liquid guide on skin slices and applying wavelengths centered at 280 or 320 nm 
(precision of 0.1 nm) at 3.0 J·cm-². There were three replicates for each group (n=3). The wavelengths were 
selected by using the monochromator described in the section 1.6.
After the irradiation, the skin slices were homogenized using a glass tissue homogenizer of 15 cm³ with 
1.0 mL of Milli-Q water. After the homogenization, the samples were transferred to Eppendorf flasks and kept 
in an ice bath, in the dark. The levels of RSNOs generated in the skin were quantified by using the NO meter 
(ISO-NO, NOMK2, World Precision Instruments, WPI, FL, USA) with an electrochemical NO sensor (ISONOP-
4 mm). To this end, an aqueous solution of copper chloride was used to allow the quantification of NO release 
from RSNO, as previously described (Oliveira et al., 2016; Silveira et al., 2016). The NO sensor was immersed 
in a solution of 10 mL of copper chloride II (CuCl2) at 0.1 mol·L-1. A volume of 200 µL of skin homogenate 
supernatant was added to the CuCl2 solution. The experiments were performed in duplicates of two independent 
experiments (n=4) and the calibration curves were obtained with aqueous solutions of freshly prepared GSNO 
(data not shown) [5]. 
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1.11. Statistical analysis
Data are presented as mean values ± standard error of the mean (SEM). Statistical analysis was 
performed using Origin Pro 2016 software by one-way ANOVA followed by Tukey post-test. Differences were 
considered statistically significant when p< 0.05.
2. Results
CS NPs have been used in different applications such as drug delivery system, tissue engineering and as 
antimicrobial agent [6–9]. The wide range of biomedical applications of CS NPs are intrinsically related to CS 
properties, such as antimicrobial effects, mucoadhesiveness, biodegradability and biocompatibility [7,8]. Firstly, 
GSH molecule, the precursor molecule of the NO donor, was encapsulated into CS NPs, followed by its 
nitrosation leading to formation of GSNO-containing CS NPs. 
GSH-CS NPs have a hydrodynamic size of 123.3 ± 1.5 nm, with a moderate polydispersity of 0.25 ± 
0.01, and a positive zeta potential of + 25.0 ± 1.1 mV, as characterized by DLS. These findings are in agreement 
with previous reports that show the formation of CS NPs for the encapsulation of different molecules (5-
fluoracil, insulin, and mercaptossunic acid)[10–13]. The particles are in the nanometer scale in aqueous medium 
with moderate polydispersity, which are desirable for biomedical applications [10]. The positive value of zeta 
potential is related to the presence of protonated amino groups in CS chemical structure and its magnitude 
indicates a good stability of the colloidal suspension of CS NPs [3,10,13]. 
The encapsulation efficiency (EE%) of GSH into CS NPs was found to be 99.6 %. The interaction of 
protonated amino groups in CS chemical structure with carboxyl groups in GSH and phosphate groups in TPP 
contributed to the high encapsulation efficiency observed for GSH into CS NPs [12,14]. This result is in 
accordance with our previous reports [2,3,12]. Moreover, Ali & Ahmed, 2018 showed an EE % of 88 and 90 % 
for protein and SiRNA encapsulated into CS NPs, respectively [15,16]. 
Fig. 3-a shows a representative AFM image of GSH-CS NPs. It can be observed a spherical shape of the 
nanoparticles with a good dispersion at solid state. Fig. 3-b shows the diameter size histogram of GSH-CS NPs, 
in which the average size was estimated to be 28.86 ± 3.30 nm. This size corresponds to average size of CS NPs 
at solid state, and it is in accordance with previously reported data. For instance, Zhang et al. reported an 
average size of 40 nm at solid state for CS NPs containing polyphenol [6] (Zhang & Zhao, 2015), and Tzeyung 
et al. reported an average size of 20 nm for CS NPs containing rotigotine, a drug used for the treatment of 
Parkinson´s disease [17].
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Fig. 3. (A) Representative atomic force microscopy (AFM) topography image and (B) diameter size histogram with a fitted log-normal curve 
(dotted black line) for GSH-CS NPs (GSH concentration of 100.0 mmol·L-1)
It should be noted that the average size of nanoparticles at solid state is expected to be lower compared 
to nanoparticle hydrodynamic size[3,18], assayed by DLS measurements, in agreement with data reported 
herein. Therefore, GSH-CS NPs were successful synthesized with a size distribution, polydispersity and shape 
suitable for biomedical applications [19].
Free thiol group of GSH incorporated into CS NPs was nitrosated by reacting with an equimolar amount 
of NaNO2, in slightly acidic aqueous suspension. NaNO2 in acid aqueous suspension is dissociate into Na+ and 
NO2- ions and it can generate the nitrous acid (HNO2), responsible for the thiol nitrosation, as represented in 
Equation 3. This reaction leads to formation of GSNO encapsulated into CS NPs. The formation of GSNO into 
CS NPs was confirmed by the detection of an absorption band at 336 nm, assigned to S-NO group (Figure 2). 
The absorption band at 336 nm was observed for GSNO-CS NPs, and absence for GSH-CS NPs, as expected 
(Figure 2).
GSH + HNO2   → GSNO + H2O Equation 3
Fig. 4. Uv spectra of GSH-CS NPs and GSNO-CS NPs. The absorption band at 336 nm confirms the formation of S-NO groups
Supplementary Data Page 9 of 10
Fig. 5 shows the CS NPs absorbance UV-vis spectrum. The CS NPs absorbs light around 200-300 nm. 
The amplitude decrease of NO generation after GSNO encapsulation into CS NPs is related to CS NPs 
absorbance of light in this range.
Fig. 5. Absorbance spectrum of CS NPs.
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